Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 31, 2007

Study Completion Date

February 29, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
BIOLOGICAL

Placebo

Subjects will be given either Placebo or PF-04603629.

BIOLOGICAL

PF-04603629

Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.

Trial Locations (2)

78229

Pfizer Investigational Site, San Antonio

85013

Pfizer Investigational Site, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00638313 - Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects | Biotech Hunter | Biotech Hunter